Related references
Note: Only part of the references are listed.Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
D. S. Hong et al.
EUROPEAN JOURNAL OF CANCER (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Jaclyn F. Hechtman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Manju L. Prasad et al.
CANCER (2016)
Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials
Juan C. Espinoza et al.
PEDIATRIC BLOOD & CANCER (2016)
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F. Farago et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
Gang Wu et al.
NATURE GENETICS (2014)
The integrated landscape of driver genomic alterations in glioblastoma
Veronique Frattini et al.
NATURE GENETICS (2013)
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the children's cancer group
JR Geyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
